An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
Open Access
- 1 January 2012
- journal article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 8 (3), 310-327
- https://doi.org/10.7150/ijbs.3524
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising therapeutic target for treating coronary heart disease. We report a novel antibody 1B20 that binds to PCSK9 with sub-nanomolar affinity and antagonizes PCSK9 function in-vitro. In CETP/LDLR-hemi mice two successive doses of 1B20, administered 14 days apart at 3 or 10 mpk, induced dose dependent reductions in LDL-cholesterol (≥ 25% for 7-14 days) that correlated well with the extent of PCSK9 occupancy by the antibody. In addition, 1B20 induces increases in total plasma antibody-bound PCSK9 levels and decreases in liver mRNA levels of SREBP-regulated genes PCSK9 and LDLR, with a time course that parallels decreases in plasma LDL-cholesterol (LDL-C). Consistent with this observation in mice, in statin-responsive human primary hepatocytes, 1B20 lowers PCSK9 and LDLR mRNA levels and raises serum steady-state levels of antibody-bound PCSK9. In addition, mRNA levels of several SREBP regulated genes involved in cholesterol and fatty-acid synthesis including ACSS2, FDPS, IDI1, MVD, HMGCR, and CYP51A1 were decreased significantly with antibody treatment of primary human hepatocytes. In rhesus monkeys, subcutaneous (SC) dosing of 1B20 dose-dependently induces robust LDL-C lowering (maximal ~70%), which is correlated with increases in target engagement and total antibody-bound PCSK9 levels. Importantly, a combination of 1B20 and Simvastatin in dyslipidemic rhesus monkeys reduced LDL-C more than either agent alone, consistent with a mechanism of action that predicts additive effects of anti-PCSK9 agents with statins. Our results suggest that antibodies targeting PCSK9 could provide patients powerful LDL lowering efficacy on top of statins, and lower cardiovascular risk.Keywords
This publication has 46 references indexed in Scilit:
- Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patentsExpert Opinion on Therapeutic Patents, 2010
- Molecular pathways and agents for lowering LDL-cholesterol in addition to statinsPharmacology & Therapeutics, 2010
- Residual dyslipidaemia after statin treatment in France: Prevalence and risk distributionArchives of Cardiovascular Diseases, 2010
- Advancing therapy for hypercholesterolemiaExpert Opinion on Pharmacotherapy, 2010
- Approach to the Patient Who Is Intolerant of Statin TherapyJournal of Clinical Endocrinology & Metabolism, 2010
- Cholesterol treatment with statins: Who is left out and who makes it to goal?BMC Health Services Research, 2010
- Recent patents on PCSK9: a new target for treating hypercholesterolemia.Recent Patents on DNA & Gene Sequences, 2009
- Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.Endocrine, Metabolic & Immune Disorders - Drug Targets, 2008
- PCSK9 as a therapeutic target of dyslipidemiaEmerging Therapeutic Targets, 2008
- PCSK9 and LDL cholesterol: unravelling the target to design the bulletTrends in Biochemical Sciences, 2008